JP7268819B2 - 抗癌剤化合物としてのヌクレオシドのジホスフェートホスホルアミデートの塩 - Google Patents

抗癌剤化合物としてのヌクレオシドのジホスフェートホスホルアミデートの塩 Download PDF

Info

Publication number
JP7268819B2
JP7268819B2 JP2020530585A JP2020530585A JP7268819B2 JP 7268819 B2 JP7268819 B2 JP 7268819B2 JP 2020530585 A JP2020530585 A JP 2020530585A JP 2020530585 A JP2020530585 A JP 2020530585A JP 7268819 B2 JP7268819 B2 JP 7268819B2
Authority
JP
Japan
Prior art keywords
alkyl
cancer
compound
independently
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020530585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505578A (ja
JP2021505578A5 (https=
Inventor
グリフィス ヒュー
サーピ ミカエラ
ペルサッチ ファブリツィオ
スルサルチク マグダレナ
Original Assignee
ニューカナ パブリック リミテッド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューカナ パブリック リミテッド カンパニー filed Critical ニューカナ パブリック リミテッド カンパニー
Publication of JP2021505578A publication Critical patent/JP2021505578A/ja
Publication of JP2021505578A5 publication Critical patent/JP2021505578A5/ja
Application granted granted Critical
Publication of JP7268819B2 publication Critical patent/JP7268819B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2020530585A 2017-12-05 2018-12-05 抗癌剤化合物としてのヌクレオシドのジホスフェートホスホルアミデートの塩 Active JP7268819B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1720279.7A GB201720279D0 (en) 2017-12-05 2017-12-05 Anticancer compounds
GB1720279.7 2017-12-05
PCT/GB2018/053525 WO2019110991A1 (en) 2017-12-05 2018-12-05 Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds

Publications (3)

Publication Number Publication Date
JP2021505578A JP2021505578A (ja) 2021-02-18
JP2021505578A5 JP2021505578A5 (https=) 2021-12-23
JP7268819B2 true JP7268819B2 (ja) 2023-05-08

Family

ID=60950385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530585A Active JP7268819B2 (ja) 2017-12-05 2018-12-05 抗癌剤化合物としてのヌクレオシドのジホスフェートホスホルアミデートの塩

Country Status (22)

Country Link
US (2) US11560400B2 (https=)
EP (2) EP3720864B1 (https=)
JP (1) JP7268819B2 (https=)
KR (1) KR20200092980A (https=)
CN (1) CN111527098A (https=)
AU (1) AU2018379713A1 (https=)
BR (1) BR112020011221A2 (https=)
CA (1) CA3082269A1 (https=)
CL (1) CL2020001479A1 (https=)
DK (1) DK3720864T3 (https=)
EA (1) EA202091218A1 (https=)
ES (1) ES2910165T3 (https=)
GB (1) GB201720279D0 (https=)
HR (1) HRP20220451T1 (https=)
IL (1) IL274808B2 (https=)
MA (2) MA51006A (https=)
MX (1) MX2020005850A (https=)
PH (1) PH12020550728A1 (https=)
PL (1) PL3720864T3 (https=)
PT (1) PT3720864T (https=)
SG (1) SG11202004342TA (https=)
WO (1) WO2019110991A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291927A (en) 2014-11-28 2022-06-01 NuCana plc Oligonucleotides containing modified nucleosides
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
CN116768949B (zh) * 2022-07-12 2026-03-03 南京工业大学 一种基于3’-脱氧腺苷经化学修饰改性的具有抗癌效应的化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2016099982A2 (en) 2014-12-15 2016-06-23 Emory University Phosphoramidates for the treatment of hepatitis b virus
JP2017535587A (ja) 2014-11-28 2017-11-30 ヌカナ バイオメド リミテッド 抗がん性化合物としての新規な２’および／または５’アミノ酸エステルホスホロアミダート３’−デオキシアデノシン誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2010135520A1 (en) 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
HUE029022T2 (en) 2011-03-01 2017-02-28 Nucana Biomed Ltd Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
WO2017106710A1 (en) 2015-12-17 2017-06-22 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
US20190085013A1 (en) 2016-03-07 2019-03-21 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2017535587A (ja) 2014-11-28 2017-11-30 ヌカナ バイオメド リミテッド 抗がん性化合物としての新規な２’および／または５’アミノ酸エステルホスホロアミダート３’−デオキシアデノシン誘導体
WO2016099982A2 (en) 2014-12-15 2016-06-23 Emory University Phosphoramidates for the treatment of hepatitis b virus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Angewandte Chemie International Edition，2008年，Vol.47, No.45，p.8719-8722
Chemical Reviews，2014年，Vol.114, No.18，p.9154-9218
Chemical Reviews，2016年，Vol.116, No.23，p.14379-14455

Also Published As

Publication number Publication date
CL2020001479A1 (es) 2020-12-18
ES2910165T3 (es) 2022-05-11
JP2021505578A (ja) 2021-02-18
US20230192750A1 (en) 2023-06-22
CN111527098A (zh) 2020-08-11
PL3720864T3 (pl) 2022-05-02
CA3082269A1 (en) 2019-06-13
HRP20220451T1 (hr) 2022-05-27
PT3720864T (pt) 2022-04-06
IL274808A (en) 2020-07-30
MA51007A (fr) 2020-10-14
MX2020005850A (es) 2020-09-07
EA202091218A1 (ru) 2020-09-14
KR20200092980A (ko) 2020-08-04
PH12020550728A1 (en) 2021-02-15
IL274808B1 (en) 2023-04-01
IL274808B2 (en) 2023-08-01
US11560400B2 (en) 2023-01-24
GB201720279D0 (en) 2018-01-17
EP4043471A1 (en) 2022-08-17
DK3720864T3 (da) 2022-04-11
AU2018379713A1 (en) 2020-07-23
WO2019110991A1 (en) 2019-06-13
EP3720864A1 (en) 2020-10-14
MA51006A (fr) 2020-10-14
SG11202004342TA (en) 2020-06-29
BR112020011221A2 (pt) 2020-11-17
US20210171566A1 (en) 2021-06-10
EP3720864B1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
AU2019216626B2 (en) Gemcitabine prodrugs
AU2024203637B2 (en) Formulations of phosphoramidate derivatives of nucleoside drugs
AU2017273117B2 (en) Phosphoramidate nucleoside derivatives as anticancer agents
US20230192750A1 (en) Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
EP3947408B1 (en) Salt of triphosphate phosphoramidates of nucleotides as anticancer compounds
HK40070782A (en) Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
HK40028717A (en) Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
HK40028717B (en) Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
EA042712B1 (ru) Соли дифосфатфосфорамидата нуклеозидов в качестве противораковых соединений
HK1262307B (en) Phosphoramidate nucleoside derivatives as anticancer agents
HK1262307A1 (en) Phosphoramidate nucleoside derivatives as anticancer agents
EA042910B1 (ru) Продукты гемцитабина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230412

R150 Certificate of patent or registration of utility model

Ref document number: 7268819

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150